```
     FILE 'HCAPLUS' ENTERED AT 11:08:43 ON 16 SEP 2009
L1       377569 S ANTIBODY OR IMMUNOGLOBULIN
L2       956540 S CANCER OR TUMOR OR NEOPLA? OR MALIGNANT
L3         5803 S BETA GLUCAN
L4       262185 S YEAST OR (SACCHAROMYCES CEREVISIAE)
L5           22 S L1 AND L2 AND L3 AND L4
L6            7 S L5 AND (PY<2005 OR AY<2005 OR PRY<2005)
```

```
=> file hcaplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.66       0.66

FILE 'HCAPLUS' ENTERED AT 11:08:43 ON 16 SEP 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 16 Sep 2009  VOL 151 ISS 12
FILE LAST UPDATED: 15 Sep 2009  (20090915/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Jun 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Jun 2009

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAplus family
of databases have been updated to include new citing references
information.  This enhancement may impact record import into
database management software.  For additional information, refer
to NEWS 9.

=> s antibody or immunoglobulin

        354450 ANTIBODY
         33355 IMMUNOGLOBULIN
L1      377569 ANTIBODY OR IMMUNOGLOBULIN

=> s cancer or tumor or neopla? or malignant

        421673 CANCER
        512533 TUMOR
        612068 NEOPLA?
         76788 MALIGNANT
L2      956540 CANCER OR TUMOR OR NEOPLA? OR MALIGNANT

=> s beta glucan

       1636651 BETA
         17567 GLUCAN
L3        5803 BETA GLUCAN
```

(BETA(W)GLUCAN)

=> s yeast or (saccharomyces cerevisiae)

232515 YEAST
101899 SACCHAROMYCES
94715 CEREVISIAE
92776 SACCHAROMYCES CEREVISIAE
(SACCHAROMYCES(W)CEREVISIAE)
L4 262185 YEAST OR (SACCHAROMYCES CEREVISIAE)

=> s l1 and l2 and l3 and l4

L5 22 L1 AND L2 AND L3 AND L4

=> s l5 and (PY<2005 or AY<2005 or PRY<2005)

25141597 PY<2005
5135698 AY<2005
4613530 PRY<2005
L6 7 L5 AND (PY<2005 OR AY<2005 OR PRY<2005)

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.85	3.51

FILE 'STNGUIDE' ENTERED AT 11:08:53 ON 16 SEP 2009

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Sep 11, 2009 (20090911/UP).

=> d l6 1-7 ti abs bib
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L6 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2009 ACS on STN
TI β Glucan as immune adjuvant for anti-cancer vaccine
AB This invention discloses a composition for enhancing the protective immunity in a subject, comprising an effective amount of a β -glucan and a vaccine, wherein the β -glucan enhances the immune response of the vaccine against cancer (or infectious agents). The infectious agents can be viruses, fungi, bacteria, or parasites. In one embodiment, the β -glucan is derived from yeast and comprises side chains attached to a β-(1,3) backbone. In another embodiment, the vaccine comprises an antibody and whole tumor cells. The invention also provides a method of enhancing protective immunity using said composition comprising the steps of (1) administering to the subject a vaccine; and (2) administering to the subject β -glucan, wherein said β -glucan has a β-(1,3) backbone and optionally β-(1,3) and/or β-(1,6) side chains, and wherein said β -glucan enhances the immune response to the anti-cancer vaccine. In another embodiment, the cancer vaccine comprises an antibody

and ≥1 components selected from the group consisting of whole tumor cells, tumor cell lysates, tumor cell-derived RNAs, proteins, peptides, carbohydrates, lipids, DNA sequences, and gene-modified tumor cells. The model vaccine used in the examples is the EL4 lymphoma tumor and anti-GD2 IgG3 monoclonal antibody combination in mouse model, that induced an antitumor response, that was further enhanced by yeast . beta.-glucan. Finally the inventors present the above vaccine combination in patients with refractory or recurrent metastatic stage 4 neuroblastoma.

AN 2009:233350 HCAPLUS <<LOGINID::20090916>>

DN 150:258240

TI β Glucan as immune adjuvant for anti-cancer vaccine

IN Cheung, Nai-Kong V.; Engstad, Rolf Einar

PA USA

SO U.S. Pat. Appl. Publ., 23pp., Cont.-in-part of U.S. Ser. No. 161,285.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20090053221	A1	20090226	US 2008-212352	20080917
	US 20060160766	A1	20060720	US 2006-334763	20060117 <--
	WO 2007084661	A2	20070726	WO 2007-US1427	20070117
	WO 2007084661	A3	20071108		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	US 20090004201	A1	20090101	US 2008-161285	20080717
PRAI	US 2006-334763	A2	20060117		
	WO 2007-US1427	W	20070117		
	US 2008-161285	A2	20080717		
	US 2001-261911P	P	20010116 <--		
	WO 2002-US1276	A2	20020115 <--		
	US 2003-621027	A2	20030716 <--		
	WO 2004-US23099	A2	20040716 <--		
	US 2005-218044	A2	20050831		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L6 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Cancer therapy using β -glucan and monoclonal antibodies

AB The invention provides methods for using neutral soluble glucan and monoclonal antibodies for antitumor therapy. Neutral soluble β (1,3; 1,6) glucan enhances the tumoricidal activity of the innate immune system by binding to the C3 complement protein receptor CR3. The glucan does not stimulate the induction of inflammatory cytokines. Also described are methods of using whole glucan particles as an immunomodulator by inducing a shift from a Th2 response to the Th1 response, leading to an enhanced

antitumor cytotoxic T-cell response.
AN 2004:308355 HCAPLUS <<LOGINID::20090916>>
DN 140:297492
TI Cancer therapy using β -glucan and monoclonal antibodies
IN Ross, Gordon D.
PA University of Louisville Research Foundation, Inc., USA
SO PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004030613	A2	20040415	WO 2003-US27975	20030904 <--
	WO 2004030613	A3	20050113		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2496508	A1	20040415	CA 2003-2496508	20030904 <--
	AU 2003295326	A1	20040423	AU 2003-295326	20030904 <--
	EP 1539194	A2	20050615	EP 2003-786508	20030904 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1694715	A	20051109	CN 2003-824893	20030904 <--
	CN 1697659	A	20051116	CN 2003-824895	20030904 <--
	CN 100363054	C	20080123		
	CN 1939335	A	20070404	CN 2006-10136269	20030904 <--
	US 20060009419	A1	20060112	US 2005-526185	20050803 <--
PRAI	US 2002-408126P	P	20020904	<--	
	CN 2003-824893	A3	20030904	<--	
	WO 2003-US27975	W	20030904	<--	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

L6 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Cancer therapy using whole glucan particles and antibodies
AB The present invention relates to methods of using whole glucan particles and complement activating antibodies for antitumor therapy. Whole glucan particles enhance the tumoricidal activity of the innate immune system by binding to the C3 complement protein receptor CR3. This binding enhances innate immune system cytotoxicity, as well as stimulating the release of activating cytokines.
AN 2004:220160 HCAPLUS <<LOGINID::20090916>>
DN 140:247055
TI Cancer therapy using whole glucan particles and antibodies
IN Ostroff, Gary R.; Ross, Gordon D.
PA Biopolymer Engineering, Inc., USA; University of Louisville Research Foundation, Inc.
SO PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004021994	A2	20040318	WO 2003-US27841	20030904 <--
	WO 2004021994	A3	20040812		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2496596	A1	20040318	CA 2003-2496596	20030904 <--
	AU 2003268486	A1	20040329	AU 2003-268486	20030904 <--
	EP 1536820	A2	20050608	EP 2003-749452	20030904 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1694715	A	20051109	CN 2003-824893	20030904 <--
	CN 1697659	A	20051116	CN 2003-824895	20030904 <--
	CN 100363054	C	20080123		
	JP 2006502167	T	20060119	JP 2004-534637	20030904 <--
	CN 1939335	A	20070404	CN 2006-10136269	20030904 <--
	US 20060165700	A1	20060727	US 2005-526175	20050729 <--
PRAI	US 2002-408126P	P	20020904 <--		
	CN 2003-824893	A3	20030904 <--		
	WO 2003-US27841	W	20030904 <--		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

L6 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Clostridial neurotoxin targeted conjugates for inhibition of secretion from non-neuronal cells
AB A method of treatment of disease by inhibition of cellular secretory processes is provided. The method has particular application in the treatment of diseases dependent on the exocytotic activity of endocrine cells, exocrine cells, inflammatory cells, cells of the immune system, cells of the cardiovascular system, and bone cells. Agents and compns. therefor, as well as methods for manufacturing these agents and compns., are provided. In a preferred embodiment a clostridial neurotoxin, substantially devoid of holotoxin binding affinity for neuronal cells of the presynaptic muscular junction, is associated with a targeting moiety. The targeting moiety is selected such that the clostridial toxin conjugate so formed may be directed to a non-neuronal target cell to which the conjugate may bind. Following binding, a neurotoxin component of the conjugate, which is capable of inhibition of cellular secretion, passes into the cytosol of the target cell by cellular internalization mechanisms. Thereafter, inhibition of secretion from the target cell is effected.
AN 2001:228744 HCAPLUS <<LOGINID::20090916>>
DN 134:247267
TI Clostridial neurotoxin targeted conjugates for inhibition of secretion from non-neuronal cells
IN Foster, Keith Alan; Chaddock, John Andrew; Purkiss, John Robert; Quinn, Conrad Padraig
PA Microbiological Research Authority, UK
SO PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001021213	A2	20010329	WO 2000-GB3669	20000925 <--
	WO 2001021213	A3	20020711		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2383470	A1	20010329	CA 2000-2383470	20000925 <--
	EP 1235594	A2	20020904	EP 2000-962721	20000925 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003509476	T	20030311	JP 2001-524636	20000925 <--
	AU 782457	B2	20050728	AU 2000-74365	20000925 <--
	US 20030180289	A1	20030925	US 2002-88665	20020814 <--
	AU 2005227383	A1	20051124	AU 2005-227383	20051027 <--
	AU 2005227383	B2	20080821		
	AU 2008241572	A1	20081127	AU 2008-241572	20081031
PRAI	GB 1999-22554	A	19990923 <--		
	WO 2000-GB3669	W	20000925 <--		
	AU 2005-227383	A3	20051027		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Immunopharmacological and immunotoxicological activities of a water-soluble (1 → 3)-β-D-glucan, CSBG from Candida spp
AB We have established a convenient, two-step procedure to solubilize the yeast cell wall (1→3)-β-D-glucan using the combination of NaClO oxidation and DMSO extraction Candida soluble β-D-glucan (CSBG) was mainly composed of a linear β-1,3 glucan with a linear β-1,6-glucan moiety. In this study, we screened for several immunopharmacol. activities of CSBG and found the following activities: (1) interleukin-6 synthesis of macrophages in vitro; (2) antagonistic effect for zymosan mediated-tumor necrosis factor synthesis of macrophages; (3) augmentation for lipopolysaccharide mediated tumor necrosis factor and nitrogen oxide syntheses of macrophages; (4) activation of alternative pathway of complement; (5) hematopoietic response on cyclophosphamide induced leukopenia; (6) the antitumor effect on ascites form tumor; (7) Enhanced vascular permeability; (8) priming effect on lipopolysaccharide triggered TNF-α synthesis; and (9) adjuvant effect on antibody production These results strongly suggested that CSBG possessed various immunopharmacol. activity.
AN 2000:235041 HCAPLUS <<LOGINID::20090916>>
DN 133:12504
TI Immunopharmacological and immunotoxicological activities of a water-soluble (1 → 3)-β-D-glucan, CSBG from Candida spp
AU Tokunaka, Kazuhiro; Ohno, Naohito; Adachi, Yoshiyuki; Tanaka, Shigenori; Tamura, Hiroshi; Yadomae, Toshiro
CS Laboratory for Immunopharmacology of Microbial Products, School of Pharmacy, Tokyo University of Pharmacy and Life Science, Tokyo, 192-0392, Japan
SO International Journal of Immunopharmacology (2000), 22(5),

383-394
CODEN: IJIMDS; ISSN: 0192-0561
PB Elsevier Science Ltd.
DT Journal
LA English
OSC.G 40 THERE ARE 40 CAPLUS RECORDS THAT CITE THIS RECORD (40 CITINGS)
RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Antigen-specific response of murine immune system toward a yeast β -glucan preparation, zymosan
AB Zymosan, a particulate β -glucan preparation from Saccharomyces cerevisiae, shows various biol. activities, including anti-tumor activity. We have previously shown that soluble β -glucan initiated anti-tumor activity was long-lived and was effective even by prophylactic treatment at 1 mo prior to tumor challenge. However, the activity by zymosan was relatively short-lived. Antigen-specific responses of mice to zymosan might be a causative mechanism. In this paper, mice were immunized with zymosan and antibody production and antigen-specific responses of lymphocytes to zymosan were analyzed. Sera of zymosan immune mice contained zymosan-specific IgG assessed by ELISA and FACS. Spleen and bone marrow cells of zymosan-immune mice showed higher cytokine production in response to zymosan. Specificity of zymosan-specific responses were also analyzed using various derivs. prepared from zymosan. These facts strongly suggested that mice recognize zymosan as antigen in addition to non-specific immune stimulant.
AN 1999:311543 HCAPLUS <<LOGINID::20090916>>
DN 131:128740
TI Antigen-specific response of murine immune system toward a yeast β -glucan preparation, zymosan
AU Miura, T.; Ohno, N.; Miura, N. N.; Adachi, Y.; Shimada, S.; Yadomae, T.
CS School of Pharmacy, Laboratory for Immunopharmacology of Microbial Products, Tokyo University of Pharmacy and Life Science, Hachioji, Tokyo, 192-0392, Japan
SO FEMS Immunology and Medical Microbiology (1999), 24(2), 131-139
CODEN: FIMIEV; ISSN: 0928-8244
PB Elsevier Science B.V.
DT Journal
LA English
OSC.G 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)
RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Interrelation of structure and antitumor effects of fungal (1→3) β-D-glucans.
AB In the last 25 yr chemical and pharmacol. studies have been focused on the non-cytotoxic, immunomodulating polysaccharides. Yeast and related fungal (1→3)-β-D-glucans, especially, those having appropriate O-6-β-D-glucosyl branches (db, 1/3 to 1/5) exhibited strong antitumor effects, and can be used as an immnumostimulator in cancer therapy. Such antitumor effects may be due to the triple helix of the backbone; (1→6)- β -glucan of lichen and also synthetic branched (1→4)-β-D-glucans were inactive. In addition, our extensive studies on the structure-activity relationship using various branched (1→3)-β-D-glucans (db, 1/25 - 3/4) showed that the distribution of the branches along the backbone and their mol. shapes may also play a role in expression of

antitumor activity, as indicated by modification of the side chains. We will discuss interrelation of structure and antitumor effects of immunomodifying glucans, e.g, an exocellular glucan of Pestalotia sp (db, 3/5), and a highly active glucan (db. 1/4) from Volvariella volvaceas, and also antibody specificities of Volvariella glucan.

AN 1996:412276 HCAPLUS <<LOGINID::20090916>>

TI Interrelation of structure and antitumor effects of fungal (1→3) β-D-glucans.

AU Misaki, A.; Kakuta, M.; Kishida, Etsu

CS Faculty Human Life Science, Osaka City University, Sumiyoshi, 558, Japan

SO Book of Abstracts, 212th ACS National Meeting, Orlando, FL, August 25-29 (1996), CARB-042 Publisher: American Chemical Society, Washington, D. C.
CODEN: 63BFAF

DT Conference; Meeting Abstract

LA English